Last edition
News about "Syndax Pharmaceuticals "
Syndax Announces Positive Revuforj Data in Acute Leukemias from Multiple Trials
Revuforj is the company's oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.
Syndax Pharmaceuticals | 09/12/2024 | By Aishwarya
Syndax Signs USD 350 Million Royalty Funding Deal with Royalty Pharma for Niktimvo
Under the terms of the agreement, Syndax received an upfront payment of USD 350 million in exchange for a 13.8 percent royalty on US net sales of Niktimvo.
Syndax Pharmaceuticals | 06/11/2024 | By Aishwarya | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy